Kyverna Moves Closer to First Autoimmune CAR-T Approval

Autolus Reports Encouraging CAR-T Data in Severe Lupus

FDA Signals Support for Autoimmune CAR-T Development

In Vivo CAR-T Shows Promise as Next-Generation Cell Therapy

CASTLE Trial Highlights Broad Potential Across Autoimmune Diseases

Novartis & Bristol Myers Squibb Pause Autoimmune CAR-T Trials Following Safety Reviews

Demonstrating Clinical, Regulatory & Commercial Validation for Next-Generation Allogeneic Cell Therapies

Demonstrating Clinical, Regulatory & Commercial Validation for Next-Generation Allogeneic Cell Therapies

9:29 am - Wednesday 2nd December 2026